41
Views
4
CrossRef citations to date
0
Altmetric
Miscellaneous

Several options for antiviral treatment trials in multiple sclerosis - but which targets should be selected?

Pages 1087-1090 | Published online: 24 Feb 2005

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Heinz Wiendl & Bernd C Kieseier. (2003) Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opinion on Investigational Drugs 12:4, pages 689-712.
Read now

Articles from other publishers (3)

Saeideh Najafi, Masood Ghane, Vahdat Poortahmasebi, Seyed Mohammad Jazayeri & Shahrokh Yousefzadeh-Chabok. (2016) Prevalence of Herpes Simplex Virus Infection in Patients With Relapsing-Remitting Multiple Sclerosis: A Case-Control Study in the North of Iran. Archives of Clinical Infectious Diseases 11:3.
Crossref
H. Wiendl, H. C. Lehmann, R. Hohlfeld, H.-P. Hartung & B. C. Kieseier. (2004) Multiple Sklerose: potenzielle Therapieansätze und Update laufender StudienMultiple sclerosis: potential therapeutic options and update of ongoing clinical trials. Der Nervenarzt 75:6, pages 536-552.
Crossref
Anthony Simmons. (2002) Clinical Manifestations and Treatment Considerations of Herpes Simplex Virus Infection. The Journal of Infectious Diseases 186:s1, pages S71-S77.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.